Wednesday, June 10, 2026
🇺🇸 FDA

pharma · No medical condition. · Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty Ltd

Anaxis Pharma clinical programs — 204 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Anaxis Pharma projects

204 ClinicalTrials.gov programs sponsored by Anaxis Pharma.

Anaxis Pharma has 204 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

204 programs

Clinical programs

Page 3 of 5

  1. G23-00

    Lacuna Pharma Pty Ltd

    healthy volunteer

    phase 1 other active

    1 trial

  2. GBP-NIB1-101

    Lacuna Pharma Pty Ltd

    rheumatoid arthritis

    phase 1 other active

    1 trial

  3. GL-ULI-1001

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  4. GL-ULI-1001

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  5. GZR33-T1D-US101

    Lacuna Pharma Pty Ltd

    Type 1 diabetes Mellitus

    phase 1 other active

    1 trial

  6. HDP-102-01

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory B-cell Malignancies

    phase 1 other active

    1 trial

  7. HS-10296-108

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations, Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations

    phase 1 other active

    1 trial

  8. HS135-002

    Lacuna Pharma Pty Ltd

    Pulmonary arterial hypertension

    phase 1 other active

    1 trial

  9. HS235-002

    Lacuna Pharma Pty Ltd

    Pulmonary arterial hypertension

    phase 1 other active

    1 trial

  10. HV-APL-A-001-24

    Lacuna Pharma Pty Ltd

    Virus diseases

    phase 1 other active

    1 trial

  11. ID-080-111

    Lacuna Pharma Pty Ltd

    Not applicable - healthy volunteer trial

    phase 1 other active

    1 trial

  12. ID-090-101

    Lacuna Pharma Pty Ltd

    Clostridioides difficile (C. difficile)

    phase 1 other active

    1 trial

  13. IMATI-10-25

    Lacuna Pharma Pty Ltd

    Acute Lymphoblastic Leukemia (Ph+ ALL), (Ph+) Chronic Myeloid Leukemia

    phase 1 other active

    1 trial

  14. INZ-701, INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency

    phase 1 small molecule active

    1 trial

  15. IP-CT-001

    Lacuna Pharma Pty Ltd

    Wound healing

    phase 1 other active

    1 trial

  16. IPH4502-101

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  17. IVACA-05-23

    Lacuna Pharma Pty Ltd

    Cystic Fibrosis

    phase 1 other active

    1 trial

  18. Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

    Lacuna Pharma Pty Ltd

    Geographic Atrophy

    phase 1 other active

    1 trial

  19. JR-441

    Lacuna Pharma Pty Ltd

    Mucopolysaccharidosis type IIIA (MPS IIIA)

    phase 1 small molecule active

    1 trial

  20. KM023-101

    Lacuna Pharma Pty Ltd

    Olmsted syndrome

    phase 1 other active

    1 trial

  21. KT-US-499-0150

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory B-cell Lymphoma

    phase 1 other active

    1 trial

  22. LA/BRP/02/25

    Lacuna Pharma Pty Ltd

    Androgenetic alopecia

    phase 1 other active

    1 trial

  23. LACOS-06-23

    Lacuna Pharma Pty Ltd

    Epileptic seizures

    phase 1 other active

    1 trial

  24. LAMOT-04-24

    Lacuna Pharma Pty Ltd

    Bipolar disorder, Epilepsy

    phase 1 other active

    1 trial

  25. LIDEXU

    Lacuna Pharma Pty Ltd

    bioavailability trial with healthy participants, therapeutic indication not studied

    phase 1 other active

    1 trial

  26. LISDE-01-25

    Lacuna Pharma Pty Ltd

    ADHD (Attention Deficit Hyperactivity Disorder), BED (Binge Eating Disorder)

    phase 1 other active

    1 trial

  27. LISDE-06-24

    Lacuna Pharma Pty Ltd

    ADHD

    phase 1 other active

    1 trial

  28. LISDE-14-24

    Lacuna Pharma Pty Ltd

    ADHD

    phase 1 other active

    1 trial

  29. LY03010/CT-EUR-102

    Lacuna Pharma Pty Ltd

    Schizophrenia

    phase 1 other active

    1 trial

  30. M6229-C002

    Lacuna Pharma Pty Ltd

    Sepsis and Septic Shock

    phase 1 other active

    1 trial

  31. MARIB-04-25

    Lacuna Pharma Pty Ltd

    cytomegalovirus (CMV) infection and/or disease that is refractory (with or without resistance) to one or more prior therapies in adult patients who have undergone hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT)

    phase 1 other active

    1 trial

  32. MESAL-02-25

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  33. MESAL-03-25

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  34. MESAL-19-24

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  35. MESAL-20-24

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  36. MP-101-02

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD)

    phase 1 other active

    1 trial

  37. Methotrexate PK (in combination with Novobiocin) in RA patients

    Lacuna Pharma Pty Ltd

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  38. Minzasolmin, UCB0599 PRD4385815

    Lacuna Pharma Pty Ltd

    Healthy Participants

    phase 1 small molecule active

    1 trial

  39. NALTR-17-24

    Lacuna Pharma Pty Ltd

    Alcohol dependence

    phase 1 other active

    1 trial

  40. NITRAIS 03/2024

    Lacuna Pharma Pty Ltd

    healthy subjects

    phase 1 other active

    1 trial

  41. NXP800 in subjects with Ovarian Cancer

    Lacuna Pharma Pty Ltd

    Platinum-resistant, ARID1a-mutated ovarian, fallopian tube and primary peritoneal carcinoma

    phase 1 other active

    1 trial

  42. O3R-5671-CL-101

    Lacuna Pharma Pty Ltd

    Inflammatory bowel diseases and psoriasis.

    phase 1 other active

    1 trial

  43. OMTX705-001

    Lacuna Pharma Pty Ltd

    Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

    phase 1 other active

    1 trial

  44. OMTX705-006 Phase 1b

    Lacuna Pharma Pty Ltd

    Advanced/Metastatic Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  45. PA0019

    Lacuna Pharma Pty Ltd

    CCI

    phase 1 other active

    1 trial

  46. PANC-GRP-3001

    Lacuna Pharma Pty Ltd

    patients with cystic fibrosis suffering from pancreatic exocrine insufficiency

    phase 1 small molecule active

    1 trial

  47. PB016-01-02

    Lacuna Pharma Pty Ltd

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  48. PM14-A-003-20

    Lacuna Pharma Pty Ltd

    Advanced solid tumors

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Anaxis Pharma have?

204 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.